Andy Yeung

Andy Yeung co-founded Asher Bio in 2019 and currently serves as its Chief Technology Officer and a Board observer. In his role, Yeung is responsible for initiating drug concepts and spearheading the engineering and technological development of antibody and cytokine candidates. His work has directly led to five preclinical research projects progressing through IND-enabling development into clinical trials. Prior to Asher Bio, Yeung spent ten years at Pfizer, culminating in his role as Director of Biotherapeutic Design and Discovery, where he led protein engineering efforts across various therapeutic areas including metabolic diseases, ophthalmology, infectious diseases, and oncology. He also spent four years as a postdoctoral fellow in the Antibody Engineering Department at Genentech. Yeung has published numerous articles in peer-reviewed journals and is an inventor on 15 issued patents and patent applications. He received his Ph.D. in Chemical Engineering and M.S. in Chemical Engineering Practice from the Massachusetts Institute of Technology, and holds a B.Sc. in Chemical Engineering from the University of Wisconsin-Madison.